AU2023256541A1 - Belumosudil for treating chronic lung allograft dysfunction - Google Patents

Belumosudil for treating chronic lung allograft dysfunction Download PDF

Info

Publication number
AU2023256541A1
AU2023256541A1 AU2023256541A AU2023256541A AU2023256541A1 AU 2023256541 A1 AU2023256541 A1 AU 2023256541A1 AU 2023256541 A AU2023256541 A AU 2023256541A AU 2023256541 A AU2023256541 A AU 2023256541A AU 2023256541 A1 AU2023256541 A1 AU 2023256541A1
Authority
AU
Australia
Prior art keywords
subject
belumosudil
lung
treatment
bos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023256541A
Other languages
English (en)
Other versions
AU2023256541A2 (en
Inventor
Corey S. CUTLER
Zachariah Michael DEFILIPP
Haesook T. KIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kadmon Corp LLC
Original Assignee
Kadmon Corp LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp LLC filed Critical Kadmon Corp LLC
Publication of AU2023256541A1 publication Critical patent/AU2023256541A1/en
Publication of AU2023256541A2 publication Critical patent/AU2023256541A2/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023256541A 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction Pending AU2023256541A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263332628P 2022-04-19 2022-04-19
US63/332,628 2022-04-19
US202263389444P 2022-07-15 2022-07-15
US63/389,444 2022-07-15
PCT/US2023/018952 WO2023205153A1 (en) 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction

Publications (2)

Publication Number Publication Date
AU2023256541A1 true AU2023256541A1 (en) 2024-12-05
AU2023256541A2 AU2023256541A2 (en) 2024-12-12

Family

ID=86330932

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023256541A Pending AU2023256541A1 (en) 2022-04-19 2023-04-18 Belumosudil for treating chronic lung allograft dysfunction

Country Status (11)

Country Link
US (1) US20250255867A1 (https=)
EP (1) EP4511036A1 (https=)
JP (1) JP2025513240A (https=)
KR (1) KR20250003657A (https=)
CN (1) CN119031914A (https=)
AU (1) AU2023256541A1 (https=)
CA (1) CA3249201A1 (https=)
IL (1) IL316410A (https=)
MX (1) MX2024012802A (https=)
TW (1) TW202404602A (https=)
WO (1) WO2023205153A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325938A (en) * 2023-07-17 2026-03-01 Kadmon Corp Llc Combination therapy including BTK inhibitor and BELUMOSUDIL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
CN113620933A (zh) 2012-10-05 2021-11-09 卡德门企业有限公司 Rho激酶抑制剂
US11311541B2 (en) * 2014-04-09 2022-04-26 Kadmon Corporation, Llc Treatment of GVHD

Also Published As

Publication number Publication date
WO2023205153A1 (en) 2023-10-26
JP2025513240A (ja) 2025-04-24
US20250255867A1 (en) 2025-08-14
CN119031914A (zh) 2024-11-26
TW202404602A (zh) 2024-02-01
CA3249201A1 (en) 2023-10-26
IL316410A (en) 2024-12-01
EP4511036A1 (en) 2025-02-26
MX2024012802A (es) 2024-11-08
KR20250003657A (ko) 2025-01-07
AU2023256541A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
Bian et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
KR102495432B1 (ko) 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
US20260103532A1 (en) Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof
KR20250088633A (ko) (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법
EP4511036A1 (en) Belumosudil for treating chronic lung allograft dysfunction
US20260027116A1 (en) Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Pidala et al. Carfilzomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium pilot phase II trial
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
EP3376869B1 (en) Treatment of autoimmune disease
RAPOR Acute eosinophilic pneumonia secondary to heroin inhalation
He et al. Voriconazole successfully treats intracranial Trichosporon asahii infection in an immunocompetent patient: a rare case report and literature review
Cattelan et al. An unusual presentation of invasive aspergillosis after lung transplantation
Shah Novel grading system for rhinocerebral mucormycosis
US20250352520A1 (en) Use of dexpramipexole for the treatment of eosinophilic copd
Fukushima et al. A case of Immunoglobulin G4-Related Scleritis and Pneumonia initially diagnosed as eosinophilic pneumonia
Karwa et al. Mucormycosis: A lethal disease
Heeney et al. PB2304 CRIZANLIZUMAB DOSE CONFIRMATION IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE: SOLACE‐KIDS TRIAL DESIGN
Demir et al. An Alternative Method for the Treatment of Resistant Hypercapnia in ARDS: Respiratory Hemodialysis.
Baughman et al. Postgraduate Course ERS Copenhagen 2005-Therapeutic options for interstitial lung diseases in 2005
CN119546306A (zh) 施用贝舒地尔以治疗慢性移植物抗宿主病的方法
JP2025541153A (ja) リルザブルチニブを投与することによる認知障害を有する対象における免疫性血小板減少症の治療方法
TW202533829A (zh) 用於治療anca相關性血管炎的因子b抑制劑
Mottal et al. PF286 EARLY ADMISSION IN INTENSIVE CARE UNIT IS ASSOCIATED WITH LOWER MORBIDITY AND MORTALITY IN ACUTE MYELOID LEUKEMIA WITH HYPERLEUKOCYTOSIS: A RETROSPECTIVE ANALYSIS
Kofler et al. “Exercise induced asthma” is not always asthma
TW202535375A (zh) 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 28 NOV 2024